CORRECTING and REPLACING Civilization Ventures Announces Portfolio Exit with Acquisition of Singular Bio by Invitae (NYSE: NVTA)

  • Singular
    Bio, Inc.
    (“Singular Bio”) is a privately held company
    developing single molecule detection technology to enable lower costs
    and expanded use of high-quality, cell-free DNA analysis, initially
    for application in non-invasive prenatal screening (NIPS).
  • Invitae,
    Inc.
    is a medical genetics company whose mission is to
    bring comprehensive genetic information into mainstream medicine to
    improve healthcare for billions of people.
  • Civilization
    Ventures
    is a deep tech venture capital firm that has
    backed dozens of innovative private companies since its inception in
    2017, including Singular Bio and Rocket Pharma (NASDAQ: RCKT)

SAN FRANCISCO–(BUSINESS WIRE)–$NVTA #diagnostics–In the headline, and in the first sentence of the release, “(NASDAQ:
NVTA)” should instead read “(NYSE: NVTA)”

The corrected release reads:

CIVILIZATION VENTURES ANNOUNCES PORTFOLIO EXIT WITH ACQUISITION OF
SINGULAR BIO BY INVITAE (NYSE: NVTA)

  • Singular
    Bio, Inc.
    (“Singular Bio”) is a privately held company
    developing single molecule detection technology to enable lower costs
    and expanded use of high-quality, cell-free DNA analysis, initially
    for application in non-invasive prenatal screening (NIPS).
  • Invitae,
    Inc.
    is a medical genetics company whose mission is to
    bring comprehensive genetic information into mainstream medicine to
    improve healthcare for billions of people.
  • Civilization
    Ventures
    is a deep tech venture capital firm that has
    backed dozens of innovative private companies since its inception in
    2017, including Singular Bio and Rocket Pharma (NASDAQ: RCKT)

Civilization
Ventures
is announcing its second portfolio exit in its third year
of operations with the acquisition of Singular Bio, a private company
developing novel technology for single molecule analysis of DNA, by
Invitae, Inc. (NYSE: NVTA), a publicly traded company at the forefront
of the genomics revolution.

“We are excited to have supported Singular Bio and its visionary
founders at a critical stage of their development as they pursued their
mission to expand access to high-quality genetic testing through their
breakthrough platform,” said Shahram Seyedin-Noor, founder and General
Partner of Civilization Ventures. Singular Bio has developed a
technology that provides single molecule analysis of a patient’s DNA,
giving exquisite sensitivity for detecting many common conditions.

“Shahram has been an invaluable partner and investor in our business,”
said Dr. Hywel Jones, co-founder and CEO of Singular Bio. “I first met
Shahram when he was founding CFO and head of Corporate Development at
NextBio – which was acquired by Illumina – and he has been a key
business partner ever since.”

Civilization Ventures was founded in 2017 by serial entrepreneur Shahram
Seyedin-Noor to invest in transformative technologies across healthcare
and biology. Prior to forming the fund, Shahram was co-founder,
Executive Chairman and Chief Business Officer of Rgenix,
a clinical-stage cancer therapeutics company. Civilization VC has been
listed by Silicon Valley Bank as one of the most prolific investors in
diagnostics in its Trends
in Healthcare Investments and Exits 2018
report.

About Civilization Ventures:

Civilization Ventures is an early-stage investor in deep tech companies
in synthetic biology and health tech, encompassing genomics and
diagnostics, digital health and AI, and personalized and regenerative
medicine.

RELATED LINKS

https://www.civilizationventures.com/

https://www.singularbio.com/

https://www.invitae.com/

Contacts

Media Contact:
Shahram
Seyedin-Noor
[email protected]

error: Content is protected !!